Protagonist Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Protagonist Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Protagonist Therapeutics: 8 sponsored US clinical trials, none currently recruiting.

Protagonist Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Polycythemia Vera, with 2 trials.

Upper-quartile sponsor footprint

Protagonist Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

NCT06033586
ACTIVE NOT RECRUITING Phase 3

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

NCT05210790
COMPLETED Phase 2

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

NCT04504383
COMPLETED Phase 2

PTG-300 in Subjects With Hereditary Hemochromatosis

NCT04202965
COMPLETED Phase 2

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

NCT04057040
COMPLETED Phase 2

Safety Study for Beta Thalassemia Subjects on PTG-300

NCT04054921
COMPLETED Phase 2

Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

NCT03802201
TERMINATED Phase 2

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

NCT02895100

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 2

Therapeutic Areas

Polycythemia Vera 2

How the Protagonist Therapeutics early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Polycythemia Vera (2 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Protagonist Therapeutics: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Protagonist Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Protagonist TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Protagonist Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Protagonist Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Protagonist Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Protagonist Therapeutics or any single study.

  • None of Protagonist Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Polycythemia Vera is the condition Protagonist Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Polycythemia Vera trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Protagonist Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.